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Background
Dendritic cells (DC) are proficient in initiating adaptive
immune responses, through the uptake and subsequent
presentation to the immune system of antigenic com-
pounds. In preclinical studies, activated DC (aDC;
DCVax®-Direct) were shown to be superior to immature
DC in clearing tumors from mice, upon intratumoral
injection.
Methods
Forty patients were enrolled in a Phase I dose escalation
trial to test the safety and feasibility of intratumoral injec-
tion of aDC in solid tumors. aDC were administered intra-
tumorally under image guidance, at a dose of 2 million, 6
million, or 15 million live, activated, autologous DC per
injection. At each injection visit (days 0, 7, 14, then weeks
8, 16 and 32), a single lesion was injected. Biopsies were
assessed for tumor necrosis and for infiltrating lympho-
cytes. Tumor size was monitored through standard ima-
ging procedures, and blood was collected for immune
monitoring. The aDC were assessed for expression of co-
stimulatory molecules and for the production of cytokines.
Results
Intratumoral injection under image guidance was generally
well tolerated and feasible. In total, 149 i.t. injections
were performed, in 17 patients at the 2 million, 20 at the
6 million, and 3 at the 15 million dose level, with mild to
moderate fevers as the most frequently observed adverse
events. Biopsies of the injected tumors showed appearance
of tumor necrosis in 62%, and T cell infiltrates in 54%. Sta-
bilization of disease was found to correlate with survival,
and with a specific cytokine profile of the aDC which is
consistent with induction of Th-1 type immune responses.
Conclusions
Intratumoral injection of autologous, activated DC is
feasible without significant toxicity in multiple solid
tumors, and can elicit local and systemic immune
responses. Specific characteristics of the injected dendri-
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